Dr. Danilov on the Efficacy of Entospletinib Plus Obinutuzumab in Relapsed/Refractory CLL

Video

Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center and professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the efficacy of entospletinib plus obinutuzumab (Gazyva) in relapsed/refractory chronic lymphocytic leukemia (CLL).

During the 2021 International Workshop on CLL, the final results of a phase 1/2 trial (NCT03010358) were presented, evaluating entospletinib, an investigational SYK inhibitor, in combination with obinutuzumab in patients with relapsed/refractory CLL. At a median follow-up of 31 months, the findings demonstrated an overall response rate (ORR) of 67% among 21 patients with CLL treated with the doublet, Danilov says. The ORR comprised 3 complete responses (CRs) and 11 partial responses. The median event-free survival was 27.5 months.

Notably, the majority of patients (62%) included on the study had high-risk cytogenetics with TP53 aberrations (n = 9), complex karyotypes (n = 6), NOTCH1 mutations (n = 2), or SF3B1 mutations (n = 4). Additionally, the modest number of CRs achieved by patients treated was in line with what was expected of B-cell receptor signaling inhibitors, Danilov explains. Finally, only one patient discontinued treatment because of toxicity, Danilov concludes.

Related Videos
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania